Recently Expired Drugs

1. Abilify Asimtufii patent expiration

ABILIFY ASIMTUFII's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(27 days ago)




Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents

2. Abilify Maintena Kit patent expiration

ABILIFY MAINTENA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(27 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Feb 28, 2016
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE

How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Advair Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(22 days ago)




Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

ADVAIR HFA family patents

Family Patents

4. Amondys 45 patent expiration

AMONDYS 45's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2026
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

AMONDYS 45 family patents

Family Patents

5. Auvi-q patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149579 KALEO INC Devices, systems and methods for medicament delivery
Jul, 2025

(7 days ago)




Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: Method of treating allergic reaction via injection

Dosage: SOLUTION

More Information on Dosage

AUVI-Q family patents

Family Patents

6. Biktarvy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Jul, 2025

(19 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 18, 2022
New Chemical Entity Exclusivity(NCE) Feb 07, 2023
M(M-82) Feb 24, 2024
Orphan Drug Exclusivity(ODE-256) Jun 18, 2026
New Indication(I-942) Feb 23, 2027
M(M-305) Apr 24, 2027
Orphan Drug Exclusivity(ODE-378) Oct 07, 2028
Orphan Drug Exclusivity(ODE-468) Feb 23, 2031

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 07 February, 2022

Market Authorisation Date: 07 October, 2021

Treatment: NA

Dosage: TABLET

How can I launch a generic of BIKTARVY before it's drug patent expiration?
More Information on Dosage

BIKTARVY family patents

Family Patents

7. Bydureon patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON family patents

Family Patents

8. Bydureon Bcise patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 20, 2020
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

9. Bydureon Pen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-224) Apr 02, 2021
M(M-240) Feb 15, 2022
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

BYDUREON PEN family patents

Family Patents

10. Descovy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Jul, 2025

(19 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 28, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Indication(I-812) Oct 03, 2022
Orphan Drug Exclusivity(ODE-284) Sep 28, 2024
Orphan Drug Exclusivity(ODE-285) Sep 28, 2024
Orphan Drug Exclusivity(ODE-457) Jan 07, 2029

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 07 January, 2022

Treatment: NA

Dosage: TABLET

How can I launch a generic of DESCOVY before it's drug patent expiration?
More Information on Dosage

DESCOVY family patents

Family Patents

11. Dojolvi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method
Jul, 2025

(25 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 30, 2025
Orphan Drug Exclusivity(ODE-311) Jun 30, 2027

Drugs and Companies using TRIHEPTANOIN ingredient

NCE-1 date: 30 June, 2024

Market Authorisation Date: 30 June, 2020

Treatment: NA

Dosage: LIQUID

More Information on Dosage

DOJOLVI family patents

Family Patents

12. Embeda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685444 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(23 days ago)

US8685443 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Jul, 2025

(23 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage

EMBEDA family patents

Family Patents

13. Entresto patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition
Jul, 2025

(11 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

14. Exondys 51 patent expiration

EXONDYS 51's oppositions filed in EPO
EXONDYS 51 IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US8486907 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE) Sep 19, 2023
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51; (i)treatment of duchenne muscular dys...

Dosage: SOLUTION

More Information on Dosage

EXONDYS 51 family patents

Family Patents

15. Farxiga patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

16. Flovent Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Jul, 2025

(22 days ago)




Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED

How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage

FLOVENT HFA family patents

Family Patents

17. Genvoya patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Jul, 2025

(19 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Sep 25, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
New Dosing Schedule(D-173) Dec 10, 2021

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 05 November, 2015

Treatment: NA

Dosage: TABLET

How can I launch a generic of GENVOYA before it's drug patent expiration?
More Information on Dosage

GENVOYA family patents

Family Patents

18. Kombiglyze Xr patent expiration

KOMBIGLYZE XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339472 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(13 days ago)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 05 November, 2010

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents

19. Nucynta patent expiration

NUCYNTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(29 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Patient Population(NPP) Jul 03, 2026
Pediatric Exclusivity(PED) Jan 03, 2027

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 03 January, 2026

Market Authorisation Date: 20 November, 2008

Treatment: Management of moderate to severe acute pain

Dosage: TABLET; SOLUTION

How can I launch a generic of NUCYNTA before it's drug patent expiration?
More Information on Dosage

NUCYNTA family patents

Family Patents

20. Nucynta Er patent expiration

NUCYNTA ER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(29 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Dosage Form(NDF) Aug 25, 2014
New Indication(I-656) Aug 28, 2015

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 20 November, 2012

Market Authorisation Date: 25 August, 2011

Treatment: Relief of moderate to severe chronic pain

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage

NUCYNTA ER family patents

Family Patents

21. Odefsey patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Jul, 2025

(19 days ago)




Drug Exclusivity Drug Exclusivity Expiration
M(M-206) Aug 21, 2020
M(M-207) Aug 21, 2020
New Chemical Entity Exclusivity(NCE) Nov 05, 2020

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 01 March, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of ODEFSEY before it's drug patent expiration?
More Information on Dosage

ODEFSEY family patents

Family Patents

22. Omegaven patent expiration

OMEGAVEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(15 days ago)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(15 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 27, 2023
Orphan Drug Exclusivity(ODE-202) Jul 27, 2025

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: 27 July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease; Treatment of liver disease through nutrition for patients under the age of 12

Dosage: EMULSION

More Information on Dosage

OMEGAVEN family patents

Family Patents

23. Osphena patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6245819 DUCHESNAY Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
Jul, 2025

(5 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 26, 2018
New Indication(I-793) Jan 25, 2022

Drugs and Companies using OSPEMIFENE ingredient

NCE-1 date: 26 February, 2017

Market Authorisation Date: 26 February, 2013

Treatment: Treatment of dyspareunia associated with menopause

Dosage: TABLET

How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage

OSPHENA family patents

Family Patents

24. Promacta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Indication(I-664) Nov 16, 2015
Orphan Drug Exclusivity(ODE) Nov 20, 2015
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE-75) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
Orphan Drug Exclusivity(ODE-210) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

NCE-1 date: 26 February, 2021

Market Authorisation Date: 20 October, 2011

Treatment: Combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia

Dosage: TABLET

How can I launch a generic of PROMACTA before it's drug patent expiration?
More Information on Dosage

PROMACTA family patents

Family Patents

25. Promacta Kit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7547719 NOVARTIS 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
Jul, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-149) Jun 11, 2018
New Indication(I-711) Jun 11, 2018
Orphan Drug Exclusivity(ODE) Aug 26, 2021
Orphan Drug Exclusivity(ODE-74) Aug 26, 2021
Pediatric Exclusivity(PED) Feb 26, 2022
ODE*(ODE*) Nov 16, 2025

Drugs and Companies using ELTROMBOPAG OLAMINE ingredient

Market Authorisation Date: 27 September, 2018

Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy

Dosage: FOR SUSPENSION

How can I launch a generic of PROMACTA KIT before it's drug patent expiration?
More Information on Dosage

PROMACTA KIT family patents

Family Patents

26. Qtern patent expiration

QTERN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-175) Apr 05, 2019
New Combination(NC) Feb 27, 2020
New Indication(I-804) May 02, 2022
New Strength(NS) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Treatment: NA

Dosage: TABLET

How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage

QTERN family patents

Family Patents

27. Qternmet Xr patent expiration

QTERNMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

QTERNMET XR family patents

Family Patents

28. Ryanodex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 22, 2021
Orphan Drug Exclusivity(ODE-69) Jul 22, 2021

Drugs and Companies using DANTROLENE SODIUM ingredient

Market Authorisation Date: 22 July, 2014

Treatment: NA

Dosage: FOR SUSPENSION

More Information on Dosage

RYANODEX family patents

Family Patents

29. Troxyca Er patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods
Jul, 2025

(23 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 19, 2019

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE

More Information on Dosage

TROXYCA ER family patents

Family Patents

30. Valtoco patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927497 NEURELIS INC Absorption enhancers for intranasal administration
Jul, 2025

(5 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 10, 2023
Orphan Drug Exclusivity(ODE-279) Jan 10, 2027
New Patient Population(NPP) Apr 15, 2028

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with ep...

Dosage: SPRAY

More Information on Dosage

VALTOCO family patents

Family Patents

31. Vemlidy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Jul, 2025

(19 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 11, 2019
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-255) Feb 04, 2023
M(M-266) Aug 22, 2023
New Patient Population(NPP) Oct 17, 2025

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: 06 November, 2019

Market Authorisation Date: 10 November, 2016

Treatment: NA

Dosage: TABLET

How can I launch a generic of VEMLIDY before it's drug patent expiration?
More Information on Dosage

VEMLIDY family patents

Family Patents

32. Ventolin Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Jul, 2025

(22 days ago)




Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 19 April, 2001

Treatment: NA

Dosage: AEROSOL, METERED

More Information on Dosage

VENTOLIN HFA family patents

Family Patents

33. Veregen patent expiration

VEREGEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770406 ANI PHARMS Medicament for the treatment of viral skin and tumour diseases
Jul, 2025

(14 days ago)




Drugs and Companies using SINECATECHINS ingredient

Market Authorisation Date: 31 October, 2006

Treatment: Treatment of genital warts

Dosage: OINTMENT

More Information on Dosage

VEREGEN family patents

Family Patents

34. Vyleesi (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6794489 COSETTE Compositions and methods for treatment of sexual dysfunction
Jun, 2025

(28 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 21, 2024

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

NCE-1 date: 22 June, 2023

Market Authorisation Date: 21 June, 2019

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VYLEESI (AUTOINJECTOR) family patents

Family Patents

35. Vyondys 53 patent expiration

VYONDYS 53's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)

US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(28 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2024
Orphan Drug Exclusivity(ODE-280) Dec 12, 2026

Drugs and Companies using GOLODIRSEN ingredient

NCE-1 date: 13 December, 2023

Market Authorisation Date: 12 December, 2019

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION

More Information on Dosage

VYONDYS 53 family patents

Family Patents

36. Winlevi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2025

(2 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 26 August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate

Dosage: CREAM

More Information on Dosage

WINLEVI family patents

Family Patents

37. Zydelig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE44599 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Jul, 2025

(5 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 23, 2019
Orphan Drug Exclusivity(ODE) Jul 23, 2021
Orphan Drug Exclusivity(ODE-70) Jul 23, 2021
Orphan Drug Exclusivity(ODE-71) Jul 23, 2021

Drugs and Companies using IDELALISIB ingredient

NCE-1 date: 23 July, 2018

Market Authorisation Date: 23 July, 2014

Treatment: For the treatment of patients with cll, fl, or sll

Dosage: TABLET

How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage

ZYDELIG family patents

Family Patents